Reviva Pharmaceuticals (RVPH) Projected to Post Earnings on Monday

Reviva Pharmaceuticals (NASDAQ:RVPH) is expected to be posting its quarterly earnings results before the market opens on Monday, April 21st. Analysts expect Reviva Pharmaceuticals to post earnings of ($0.22) per share for the quarter.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.07. On average, analysts expect Reviva Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Reviva Pharmaceuticals Stock Up 10.4 %

Shares of RVPH opened at $0.78 on Friday. The company has a market cap of $36.57 million, a P/E ratio of -0.70 and a beta of 0.05. Reviva Pharmaceuticals has a fifty-two week low of $0.49 and a fifty-two week high of $4.28. The firm’s 50 day moving average price is $1.10 and its 200 day moving average price is $1.39.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. HC Wainwright reduced their price objective on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. Roth Mkm started coverage on shares of Reviva Pharmaceuticals in a report on Friday, January 10th. They set a “buy” rating and a $7.00 price target for the company. Roth Capital upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 10th. Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research note on Friday, January 10th. Finally, D. Boral Capital cut their price target on Reviva Pharmaceuticals from $15.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Reviva Pharmaceuticals currently has an average rating of “Buy” and an average price target of $10.00.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.